Joseph Kiani - Masimo Chairman of the Board, CEO

MASI Stock  USD 188.77  2.57  1.38%   

Chairman

Mr. Joseph E. Kiani is the Chairman of the Board, Chief Executive Officer of Masimo Corporationration Mr. Kiani is an inventor on more than 100 patents related to signal processing, sensors and patient monitoring, including patents for the invention of Measurethrough motion and lowperfusion pulse oximetry. Since September 2016, Mr. Kiani has served on the Board of Directors of Stereotaxis, Inc., a manufacturer of robotic cardiology instrument navigation systems. From 1998 to March 2013, Mr. Kiani served on the Board of Directors of Saba Software, Inc., a publiclytraded software company focused on human capital development and management solutions since 1989.
Age 59
Tenure 36 years
Address 52 Discovery, Irvine, CA, United States, 92618
Phone949 297 7000
Webhttps://www.masimo.com
Kiani holds a B.S.E.E. and an M.S.E.E. from San Diego State University. In addition to Mr. Kiani’s role at Masimo, he is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare, Chairman of the Patient Safety Movement Foundation, Chairman and CEO of the Patient Safety Movement Coalition and Chairman and CEO of Cercacor Laboratories, Inc. He also sits on the Boards of Directors of Atheer Labs, CHOC Children’s Orange/CHOC Children’s at Mission Hospital, Bioniz Therapeutics, Inc. and the Medical Device Manufactures Association. As Masimo’s founder, Chief Executive Officer and Chairman of the Board since our formation in 1989, Mr. Kiani has the deepest understanding of Masimo, our history, our culture and our technology.

Masimo Management Efficiency

As of now, Masimo's Return On Tangible Assets are decreasing as compared to previous years. The Masimo's current Return On Capital Employed is estimated to increase to 0.14, while Return On Equity is projected to decrease to 0.10. As of now, Masimo's Other Current Assets are increasing as compared to previous years. The Masimo's current Total Current Assets is estimated to increase to about 1.3 B, while Other Assets are projected to decrease to under 327.8 K. Masimo's management efficiency ratios could be used to measure how well Masimo manages its routine affairs as well as how well it operates its assets and liabilities.
Masimo currently holds 727.9 M in liabilities with Debt to Equity (D/E) ratio of 0.83, which is about average as compared to similar companies. Masimo has a current ratio of 2.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Masimo's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 8 records

CHAIRMAN Age

William KozyLivaNova PLC
72
Thomas BurnsGlaukos Corp
64
Mark TryniskiCONMED
60
Curt HartmanCONMED
61
Marilyn NelsonInspire Medical Systems
81
Adam ElsesserPenumbra
62
Adam JDPenumbra
63
William LinkGlaukos Corp
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company was incorporated in 1989 and is headquartered in Irvine, California. Masimo Corp operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 2200 people. Masimo (MASI) is traded on NASDAQ Exchange in USA. It is located in 52 Discovery, Irvine, CA, United States, 92618 and employs 3,600 people. Masimo is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Masimo Leadership Team

Elected by the shareholders, the Masimo's board of directors comprises two types of representatives: Masimo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Masimo. The board's role is to monitor Masimo's management team and ensure that shareholders' interests are well served. Masimo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Masimo's outside directors are responsible for providing unbiased perspectives on the board's policies.
Blair Tripodi, Chief Division
Yongsam Lee, CIO and Executive VP
Tetsuro Maniwa, President Japan
Catherine Szyman, Chief Officer
Steven Barker, Chairman Officer
Micah Young, CFO, Executive Vice President
Tao Levy, Executive Vice President - Business Development
Micah CPA, Executive CFO
Eli Kammerman, Investor Relations Officer
Jon Coleman, President - Worldwide Sales, Professional Services and Medical Affairs
Joseph Kiani, Chairman of the Board, CEO
Thomas McClenahan, General VP
Michelle Brennan, Interim Director
Paul Hataishi, Senior Officer
Bilal Muhsin, Executive Vice President Engineering, Marketing & Regulatory Affairs
Thomas JD, General VP
Anand Sampath, Executive Research

Masimo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Masimo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Masimo offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Masimo's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Masimo Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Masimo Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Masimo. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more detail on how to invest in Masimo Stock please use our How to Invest in Masimo guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Masimo. If investors know Masimo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Masimo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.10)
Earnings Share
(5.72)
Revenue Per Share
39.295
Quarterly Revenue Growth
0.094
Return On Assets
0.0061
The market value of Masimo is measured differently than its book value, which is the value of Masimo that is recorded on the company's balance sheet. Investors also form their own opinion of Masimo's value that differs from its market value or its book value, called intrinsic value, which is Masimo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Masimo's market value can be influenced by many factors that don't directly affect Masimo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Masimo's value and its price as these two are different measures arrived at by different means. Investors typically determine if Masimo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Masimo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.